Cargando…

Assessment of sarcopenia as a predictor of poor overall survival for advanced non-small-cell lung cancer patients receiving salvage anti-PD-1 immunotherapy

BACKGROUND: Sarcopenia, which is defined as the loss of skeletal muscle mass, has been identified as a poor prognostic factor for cancer patients. This study sought to elucidate the effects of sarcopenia on the outcomes of advanced non-small cell lung cancer (NSCLC) patients receiving salvage anti-p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yixing, Chen, Ping, Huang, Jinsheng, Liu, Minghui, Peng, Dingsheng, Li, Zichun, Chen, Tao, Hong, Shaodong, Zhou, Yixin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8756219/ https://www.ncbi.nlm.nih.gov/pubmed/35071495 http://dx.doi.org/10.21037/atm-21-6578

Ejemplares similares

Adjuvant therapy in completely resected, EGFR-mutant non-small cell lung cancer: a comparative analysis of treatment efficacy between EGFR-TKI and anti-PD-1/PD-L1 immunotherapy
por: Li, Zichun, et al.
Publicado: (2023)

LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy
por: Luo, Linfeng, et al.
Publicado: (2023)

Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy
por: Bolte, Fabian J., et al.
Publicado: (2022)

High Mean Corpuscular Volume as a Predictor of Poor Overall Survival in Patients with Esophageal Cancer Receiving Concurrent Chemoradiotherapy
por: Li, Ke-jie, et al.
Publicado: (2020)

The impact of sarcopenia on overall survival in patients with pan-RAS wild-type colorectal liver metastasis receiving hepatectomy
por: Yang, Yao-Ren, et al.
Publicado: (2023)

Sarcopenia and visceral adiposity predict poor overall survival in hepatocellular carcinoma patients after curative hepatic resection
por: Jang, Hee Yoon, et al.
Publicado: (2021)

Sarcopenia as a Possible Negative Predictor of Limb Salvage in Patients with Chronic Limb-Threatening Ischemia
por: Taniguchi, Ryosuke, et al.
Publicado: (2019)

Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab
por: Gillen, J., et al.
Publicado: (2019)

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia
por: Chen, Cunte, et al.
Publicado: (2021)

Deciphering transcriptomic determinants of the divergent link between PD-L1 and immunotherapy efficacy
por: Li, Anlin, et al.
Publicado: (2023)

Increased PD-1(+)Foxp3(+) γδ T cells associate with poor overall survival for patients with acute myeloid leukemia
por: Zheng, Jiamian, et al.
Publicado: (2022)

Chemotherapy combined with antiangiogenic drugs as salvage therapy in advanced melanoma patients progressing on PD-1 immunotherapy
por: Wang, Xuan, et al.
Publicado: (2020)

Burden of tumor mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival
por: Wood, Mary A., et al.
Publicado: (2020)

Increased coexpression of PD-L1 and TIM3/TIGIT is associated with poor overall survival of patients with esophageal squamous cell carcinoma
por: Wang, Peipei, et al.
Publicado: (2021)

Association between Fluoxetine Use and Overall Survival among Patients with Cancer Treated with PD-1/L1 Immunotherapy
por: Magagnoli, Joseph, et al.
Publicado: (2023)

Evaluating relapse-free survival as an endpoint for overall survival in adjuvant immunotherapy trials
por: Li, Yuanfang, et al.
Publicado: (2023)

Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019)

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy
por: Chen, Chian-Wei, et al.
Publicado: (2023)

Real‐world data prognostic model of overall survival in patients with advanced NSCLC receiving anti‐PD‐1/PD‐L1 immune checkpoint inhibitors as second‐line monotherapy
por: Julian, Cristina, et al.
Publicado: (2022)

Sarcopenia is a prognostic factor for overall survival in elderly patients with head-and-neck cancer
por: Chargi, N., et al.
Publicado: (2019)

Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitor
por: He, Li-Na, et al.
Publicado: (2023)

Pre-sarcopenia is the prognostic factor of overall survival in early-stage hepatoma patients undergoing radiofrequency ablation
por: Yeh, Wen-Shuo, et al.
Publicado: (2020)

Sarcopenia is associated with worse surgical complications but not relapse-free survival and overall survival in patients with retroperitoneal liposarcoma
por: Zhao, Mingkun, et al.
Publicado: (2022)

Higher serum sPD-L1 levels after radiotherapy indicate poor outcome in hepatocellular carcinoma patients
por: Zhang, Yang, et al.
Publicado: (2022)

Sarcopenia does not limit overall survival after interstitial brachytherapy for breast cancer liver metastases
por: Thormann, Maximilian, et al.
Publicado: (2022)

Sarcopenia reduces overall survival in unresectable oesophageal cancer: a systematic review and meta‐analysis
por: Jogiat, Uzair M., et al.
Publicado: (2022)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

P712: SOLUBLE PD-L1 PREDICT POOR OVERALL SURVIVAL AND DISEASE PROGRESSION IN PATIENTS WITH DE NOVO MYELODYSPLASTIC SYNDROME
por: Yang, Xingcheng, et al.
Publicado: (2023)

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model
por: Du, Yang, et al.
Publicado: (2017)

PD-L1 Protein Expression Is Associated With Good Clinical Outcomes and Nomogram for Prediction of Disease Free Survival and Overall Survival in Breast Cancer Patients Received Neoadjuvant Chemotherapy
por: Chen, Li, et al.
Publicado: (2022)

Sarcopenia Was a Poor Prognostic Predictor for Patients With Advanced Lung Cancer Treated With Immune Checkpoint Inhibitors
por: Li, Shuluan, et al.
Publicado: (2022)

Appendicular Skeletal Muscle Mass Associated with Sarcopenia as a Predictor of Poor Functional Outcomes in Ischemic Stroke
por: Lee, Sang-Hun, et al.
Publicado: (2023)

No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma
por: Safi, Mohammed, et al.
Publicado: (2021)

Sarcopenia is poor prognostic factor in older patients with locally advanced rectal cancer who received preoperative or postoperative chemoradiotherapy
por: Park, Song Ee, et al.
Publicado: (2018)

Modeling Sarcopenia to Predict Survival for Patients With Nasopharyngeal Carcinoma Receiving Concurrent Chemoradiotherapy
por: Hua, Xin, et al.
Publicado: (2021)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
por: Yu, Jiangyong, et al.
Publicado: (2022)

The combination of sarcopenia and biochemical factors can predict the survival of hepatocellular carcinoma patients receiving transarterial chemoembolization
por: Chien, Tzu-Ping, et al.
Publicado: (2022)

High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma
por: Chen, Cunte, et al.
Publicado: (2022)

First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
por: Zhou, Yixin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1sdp5ar5ea8bc4vqn8k7hnngdh